Abstract
2,3-dihydrobenzo[b][1,4]oxathiine represents a valuable pharmacophoric heterocyclic nucleus known since very long time. Initially, together with some patents reporting the use of these compounds as herbicides or lipogenesis inhibitors, several papers reported their ability as melatonin, histamine and serotonin receptor ligands, α-adrenoreceptor blockers as well as non-glycoside sweeteners. This wide range of biological activities has been recently further improved by studies stating their activity as antimycotics, multi-defense antioxidants and estrogen receptor ligands. The last insights regarding the preparation, the biological activity and the structure activity relationship (SAR) of derivatives containing the dihydrobenzoxathiine skeleton will be discussed in this review.
Keywords: 2,3-Dihydrobenzo[b][1,4]oxathiines, 4-thiaflavanes, sweeteners, antimicotic activity, multi-defense antioxidants, selective estrogen receptor modulators
Current Medicinal Chemistry
Title: Dihydrobenzo[1,4]oxathiine: A Multi-Potent Pharmacophoric Heterocyclic Nucleus
Volume: 17 Issue: 10
Author(s): C. Viglianisi and S. Menichetti
Affiliation:
Keywords: 2,3-Dihydrobenzo[b][1,4]oxathiines, 4-thiaflavanes, sweeteners, antimicotic activity, multi-defense antioxidants, selective estrogen receptor modulators
Abstract: 2,3-dihydrobenzo[b][1,4]oxathiine represents a valuable pharmacophoric heterocyclic nucleus known since very long time. Initially, together with some patents reporting the use of these compounds as herbicides or lipogenesis inhibitors, several papers reported their ability as melatonin, histamine and serotonin receptor ligands, α-adrenoreceptor blockers as well as non-glycoside sweeteners. This wide range of biological activities has been recently further improved by studies stating their activity as antimycotics, multi-defense antioxidants and estrogen receptor ligands. The last insights regarding the preparation, the biological activity and the structure activity relationship (SAR) of derivatives containing the dihydrobenzoxathiine skeleton will be discussed in this review.
Export Options
About this article
Cite this article as:
Viglianisi C. and Menichetti S., Dihydrobenzo[1,4]oxathiine: A Multi-Potent Pharmacophoric Heterocyclic Nucleus, Current Medicinal Chemistry 2010; 17 (10) . https://dx.doi.org/10.2174/092986710790820697
DOI https://dx.doi.org/10.2174/092986710790820697 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanoparticles-Based Treatment for Bone Metastasis
Current Drug Targets A Hybrid Evolutionary System for Automated Artificial Neural Networks Generation and Simplification in Biomedical Applications
Current Bioinformatics Cardiovascular-Related
Current Bioactive Compounds Towards More Efficient Glutathione Peroxidase Mimics: Substrate Recognition and Catalytic Group Assembly
Current Medicinal Chemistry New Technological Developments in the Clinical Imaging of Atherosclerotic Plaque
Current Pharmaceutical Design Editorial [Hot Topic: Modifying Cardiovascular Risk Factors: Epidemiology and Characteristics of Hypertension-Related Disorders (Executive Guest Editor: Aurelio Leone)]
Current Pharmaceutical Design Inflammatory Biomarkers, Depressive Symptoms and Falls Among the elderly in Panama
Current Aging Science Predictive In Silico Studies of Human 5-hydroxytryptamine Receptor Subtype 2B (5-HT2B) and Valvular Heart Disease
Current Topics in Medicinal Chemistry Current Evidence Regarding Low-carb Diets for The Metabolic Control of Type-2 Diabetes
Current Diabetes Reviews Molecular Mechanisms of the Antiatherogenic Action of Adiponectin
Vascular Disease Prevention (Discontinued) Editorial (Thematic Issue: The Changing Face of Metabolic Syndrome and its Components in the Light of Current Knowledge)
Current Vascular Pharmacology Endothelial Progenitor Cells in Prehypertension
Current Pharmaceutical Design The Role of Aryl Hydrocarbon Receptor-Regulated Cytochrome P450 Enzymes in Glioma
Current Pharmaceutical Design Editorial (Thematic Issue: Novel Targets and Biomarkers for Anti-atherosclerotic Therapy)
Current Pharmaceutical Design Cardiac Oxidative Stress and Inflammation are Similar in SAMP8 and SAMR1 Mice and Unaltered by Curcumin and Ginkgo biloba Extract Intake
Current Pharmaceutical Biotechnology Approaches and Recent Trends in Gene Delivery for Treatment of Atherosclerosis
Recent Patents on Drug Delivery & Formulation Vaccines for Patients with COPD
Recent Patents on Inflammation & Allergy Drug Discovery Antioxidants in Health, Disease and Aging
CNS & Neurological Disorders - Drug Targets 3D Printing as a Significant Achievement for Application in Posttraumatic Surgeries - A Literature Review
Current Medical Imaging Complex Atheromatosis of the Aortic Arch in Cerebral Infarction
Current Cardiology Reviews